Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma
Telo Genomics Announces Termination of Investor Relations Agreement
Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma
Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman
Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing
Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement
Telo Genomics Closes First Tranche of Convertible Debentures Financing
Telo Genomics Announces Appointment of John Price as Chief Financial Officer
Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000
Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program
Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting
Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th
Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025
American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition
Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update
Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting
Telo Geonomics Announces Engagement of Investor Relations Service Provider
Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference
Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference
International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting
Telo Genomics Corp. to File Statement of Defence and Counterclaim to Lawsuit Filed by Former President
Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma
Telo Genomics Receives New Client Tier under Intellectual Property Ontario (IPON)
European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress
Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025
Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors
Telo Genomics Appoints Baechler Executive Chairman of The Board of Directors
Telo Genomics Announces Expanded Partnership with Trusted Health Advisors
Telo Genomics Closes Oversubscribed $2.5 Million Private Placement
Telo Genomics Announces Private Placement for up to $2 Million
Telo Genomics Receives Approval from the Intellectual Property Ontario Program (IPON)
Telo Genomics Expands its Strategic Collaboration with Mayo Clinic
Telo Genomics Presents New Performance Data for Its Smoldering Myeloma Prognostic Test
Telo Genomics Assessing MRD Status in TELO-DMRD Study
Telo Genomics Receives CLIA Certification
Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP
Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024
Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology
Telo Genomics and Emery Pharma Announce Collaboration
Telo Genomics Receives Accreditation from College of American Pathologists
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US
Telo Genomics Gears up for American Society of Hematology Conference
Telo Genomics Launches Physician Experience Program in the United States
Telo Genomics Advances to the Final Stage of Accreditation from The College of American Pathologists
American Society of Hematology (ASH) Accepts Validation Data from Telo Genomics for Presentation at Upcoming Annual Meeting
Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation
Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM - An Important Commercial Milestone Achieved
Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting